GGrantIndex
← Leaderboards

Laurel A Habel

University Of Tx Md Anderson Can Ctr

$11,156,215
Attributed
$15,419,832
Total exposure
12
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.2M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$15,419,832 · 12

By mechanism

R01$15,362,381 · 8
R03$55,173 · 1
P41$2,278 · 3

Top collaborators

Most similar at University Of Tx Md Anderson Can Ctr

Same institution · by research overlap

Others in their field

Top investigators on “Cancer Risk

Research focus

Cancer RiskMammographyProgramsCaliforniaBaseDensityCohortGenesResourcesDiagnosisMammary Gland ParenchymaBreast Cancer Risk FactorTissuesWomanMalignant Breast NeoplasmMalignant NeoplasmsPathway InteractionsRisk FactorsEtiologyEnvironmentDatabasesMemberHealthcareGenome Wide Association Study

Grant awards (38)

Radiomic and genomic predictors of breast cancer risk$697,652
R01 · FY2025 · CA
Radiomic and genomic predictors of breast cancer risk$662,768
R01 · FY2024 · CA
Genomic and Transcriptomic Analysis of Mammographic Density$495,945
R01 · FY2023 · CA
Radiomic and genomic predictors of breast cancer risk$681,064
R01 · FY2022 · CA
Genomic and Transcriptomic Analysis of Mammographic Density$474,559
R01 · FY2022 · CA
Radiomic and genomic predictors of breast cancer risk$712,593
R01 · FY2021 · CA
Genomic and Transcriptomic Analysis of Mammographic Density$484,243
R01 · FY2021 · CA
Genomic and Transcriptomic Analysis of Mammographic Density$501,617
R01 · FY2020 · CA
Genome-wide Pleiotropy Scan across Multiple Cancers$648,955
R01 · FY2018 · CA
Genome-wide Pleiotropy Scan across Multiple Cancers$648,968
R01 · FY2017 · CA
Genome-wide Pleiotropy Scan across Multiple Cancers$664,225
R01 · FY2016 · CA
Genome-Wide Association Study of Mammographic Density$284,499
R01 · FY2016 · CA
Mammographic Density & Prognosis among Breast Cancer Intrinsic Subtypes$448,669
R01 · FY2015 · CA · contact PI
Mammographic Density & Prognosis among Breast Cancer Intrinsic Subtypes$519,570
R01 · FY2014 · CA · contact PI
Mammographic Density & Prognosis among Breast Cancer Intrinsic Subtypes$521,568
R01 · FY2013 · CA · contact PI
Pharmaceuticals and Cancer$399,257
R01 · FY2013 · CA · contact PI
Mammographic Density & Prognosis among Breast Cancer Intrinsic Subtypes$562,665
R01 · FY2012 · CA · contact PI
Pharmaceuticals and Cancer$315,479
R01 · FY2012 · CA · contact PI
Pharmaceuticals and Cancer$314,943
R01 · FY2011 · CA · contact PI
Pharmaceuticals and Cancer$324,358
R01 · FY2010 · CA · contact PI
DEVELOPMENT OF TYPE II INHIBITORS FOR JNK3$346
P41 · FY2010 · RR · contact PI
Pharmaceuticals and Cancer$323,573
R01 · FY2009 · CA · contact PI
DEVELOPMENT OF TYPE II INHIBITORS FOR JNK3$213
P41 · FY2009 · RR · contact PI
Pharmaceuticals and Cancer$299,444
R01 · FY2008 · CA · contact PI
DEVELOPMENT OF TYPE II INHIBITORS FOR JNK3$1,719
P41 · FY2008 · RR · contact PI
Pharmaceuticals and Cancer$305,502
R01 · FY2007 · CA · contact PI
Pharmaceuticals and Cancer$305,716
R01 · FY2006 · CA · contact PI
Mammographic Density in a Multi-Ethnic Cohort$391,857
R01 · FY2005 · CA
Pharmaceuticals and Cancer$304,215
R01 · FY2005 · CA
Mammographic Density in a Multi-Ethnic Cohort$524,917
R01 · FY2004 · CA
Pharmaceuticals and Cancer$340,503
R01 · FY2004 · CA
Mammographic Density in a Multi-Ethnic Cohort$546,879
R01 · FY2003 · CA
DCIS--MAMMOGRAPHIC FEATURES AND PROGNOSIS$277,895
R01 · FY2003 · CA
Mammographic Density in a Multi-Ethnic Cohort$545,866
R01 · FY2002 · CA
DCIS--MAMMOGRAPHIC FEATURES AND PROGNOSIS$292,466
R01 · FY2002 · CA
DCIS--MAMMOGRAPHIC FEATURES AND PROGNOSIS$273,451
R01 · FY2001 · CA
DCIS--MAMMOGRAPHIC FEATURES AND PROGNOSIS$266,500
R01 · FY2000 · CA
MAMMOGRAPHIC DENSITY AND BREAST CANCER AFTER DCIS$55,173
R03 · FY2000 · CA